PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet 1 of 3

| Complete if Known | |
|---|---|
| Application Number | 10/586,892 |
| Filing Date | February 9, 2007 |
| First Named Inventor | David S. Lawrence |
| Art Unit | 1636 |
| Examiner Name | Jennifer Ann Dunston |
| Attorney Docket Number | 96700/1160 |

## NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 1 | BOOMS P et al. "Novel exon skipping mutation in the fibrillin-1 gene: two 'hot spots' for the neonatal Marfan syndrome." Clin. Genet. 55:110-7, 1999. Abstract only | |
| | 2 | DU M et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. PNAS 105: 2064-69, 2. | |
| | 3 | DURIEZ B et al. "An exon-skipping mutation in the btk gene of a patient with X-linked agammaglobulinemia and isolated growth hormone deficiency." FEBS Lett. 1994 | |
| | | June 13;346(2-3):165-70. Abstract only | |
| | 4 | ENZMANN H et al. Damage to mitochondrial DNA induced by the quinolone Bay y 3118 in embroyonic turkey liver. Mutat. Res. 425:213-24, 1999. Abstract only | |
| | 5 | FERNANDES R et al. Incorporation of structurally defective type II collagen into cartilage matrix in kniest chondrodysplasia. Arch Biochem Biophys 355:282-90 1998 Abstract | |
| | 6 | FOGLI A et al. "Intracellular levels of the LIS1 protein correlate with clinical and neuroradiological findings in patients with classical lissencephaly." | |
| | | Ann Neurol. 1999 Feb;45(2):154-61. Abstract only | |
| | 7 | GUILFORD P et al. "E-cadherin germline mutations in familial gastric cancer." Nature 1998 Mar. 26;392(6674):402-5. Abstract only | |
| | 8 | HIRANO M et al. Dominant negative effect of GTP cyclohydrolase I mutations in dopa-responsive hereditary progressive dystonia. Ann Neurol. 44:365-71 1998 Abstract | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet 2 of 3

| *Complete if Known* | |
|---|---|
| **Application Number** | 10/586,892 |
| **Filing Date** | February 9, 2007 |
| **First Named Inventor** | David S. Lawrence |
| Art Unit | 1636 |
| Examiner Name | Jennifer Ann Dunston |
| Attorney Docket Number | 96700/1160 |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 9 | HIRAWAT S et al. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation supressor, following single- and multiple-dose administration to | |
| | | healthy male and female adult volunteers. Clin. Pharm. 2007; 47:430-444. | |
| | 10 | KEREM E et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. The Lancet vol. 372: 719-27, 2008. | |
| | 11 | LAUMONNIER Fet al. X-Linked mental retardation and autism are associated with a mutation in the NLGN4 gene, a member of the neuroligin family. Am J Hum. Genet. 74:552-7, 2004. | |
| | 12 | MACOSKA J et al. "Loss of expression of human spectrin Src homology domain binding protein 1 is associated with 10p loss in human prostatic adenocarcinoma." | |
| | | Neoplasia, 3:99-104, 2001. | |
| | 13 | MERCURI E et al. "Muscle MRI findings in a three-generation family affected by Bethlem myopathy." Eur. J. Paediatr. Neurol. 2002;6(6):309-14. Abstract only | |
| | 14 | NICHOLLS A et al. "An exon skipping mutation of a type V collagen gene (COL5A1) in Ehlers-Danolos syndrome." J. Med. Genet. 1996;33:940-946. | |
| | 15 | THOMAS A et al. "Electrochemical characteristics of five quinolone drugs and their effect on DNA damage and repair in Escherichia coli." J. Antimicrob. Chemother. 1990 | |
| | | May;25(5):733-44. Abstract only | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet 3 of 3

| *Complete if Known* | |
|---|---|
| Application Number | 10/586,892 |
| Filing Date | February 9, 2007 |
| First Named Inventor | David S. Lawrence |
| Art Unit | 1636 |
| Examiner Name | Jennifer Ann Dunston |
| Attorney Docket Number | 96700/1160 |

**NON PATENT LITERATURE DOCUMENTS**

| Examiner Initials* | Cite No.[1] | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T[2] |
|---|---|---|---|
| | 16 | Tiller G et al. "A recurrent RNA-splicing mutation in the SEDL gene causes X-linked spondyloepiphyseal dysplasia tarda." Am. J. Hum. Genet. 68:1398-1407, 2001. | |
| | 17 | SPAYDE E et al. "Exon skipping mutation in the COL9A2 gne in a family with multiple epiphyseal dysplasia." Matrix Biol. 19:121-8 2000. Abstract only | |
| | 18 | VAILLY et al. "Identification of a homozygous exon-skipping mutation in the LAMC2 gene in a patient with Herlitz's junctional epidermolysis bullosa." | |
| | | J. Invest. Dermatol. 1995 Mar;104(3):434-7. Abstract only | |
| | 19 | WELCH E et al. "PTC124 targets genetic disorders caused by nonsense mutations." Nature 447:87-91, 2007. | |
| | 20 | YEOWELL H et al. "Ehlers-Danlos syndrome type VI results from a nonsense mutation and a splice site-mediated exon-skipping mutation in the lysyl hydroxylase gene. | |
| | | Proc. Assoc. Am. Physicians 1997 Jul;109(4):383-96. Abstract only | |
| | 21 | Selleck Chemicals, online catalog, PTC124 (Ataluren) 2010 | |
| | | | |
| | | | |

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.